Light Ai Inc. · NEO:ALGO
Light Ai — Investor Presentation (July 2026)
24 slides from Light Ai's investor presentation, Jul 1, 2026
Slide 1: Detecting Infectious Diseases Instantly
Detecting Infectious Diseases Instantly Applying AI to images to identify disease in seconds – a patented, app-based software solution Leading the Digital Health Paradigm Shift Corporate Presentation July 2026 Non-Confidential - Property of Light AI Inc. CBOE CA: ALGO FSE: 0HC OTCQB: OHCFF
Slide 2: Disclaimer
Disclaimer This corporate presentation of Light AI Inc. (the “Company”) and the information contained herein actual results may differ materially from those in the forward-looking statements. Readers are reliance on forward-looking statements due to the inherent uncertainty therein. All (the “Presen
Slide 3: Global Burden of Pharyngitis
Global Burden of Pharyngitis Global Impact of Pharyngitis Of the 2.5 Billion cases annually, about 615 million people infected by Viral and Group A Global Pharyngitis; Symptoms vs. Antibiotic Use Streptococcus (GAS) pharyngitis annually* killing as many as malaria**. Without treatment GAS can cause
Slide 4: Highlights
Highlights 2.5B cases of pharyngitis (sore throat) cases treated Commercialization Initial B2B focus on professional medical community Large Market with expansion to B2C offering annually, approx. 20% bacterial Strep A, 615M SAM. Misdiagnosis drives antibiotic misuse and Antimicrobial Four initial p
Slide 5: Paradigm Shift for Medical Clinical Management
Paradigm Shift for Medical Clinical Management Current Medical Diagnostics System • Time Consuming (up to 72hrs for results) • Expensive ($20-$60 per test) • Inefficient (patient must return for prescription) 24-72+ Hours Health Care Provider Lab Test Lab Results Follow-Up Visit Treatment Plan Point
Slide 6: Light AI QuickScan
Light AI QuickScan Light AI QuickScan AI-Driven SaMD Light AI’s software uses advanced AI algorithms to accurately distinguish viral from bacterial pharyngitis through image analysis Integration and Accessibility The solution integrates with existing imaging devices and is accessible via mobile devi
Slide 7: Global Pharyngitis $16B-$30B TAM – Light AI Opportunity
Global Pharyngitis $16B- $30B TAM – Light AI Opportunity AI-Triage, SaMD, and Diagnostics Market Sizing (Annual, Global) TAM ($B) 10 9 8 7 6 5 4 3 2 1 0 AI-Triage SaMD Diagnostics Assumes 2.25B global pharyngitis episodes annually. AI-Triage applicable to ~80% ($2–5B TAM) | SaMD applicable to ~60% (
Slide 8: Path to $100M+ ARR: Light AI Global SAM → SOM
Path to $100M+ ARR: Light AI Global SAM → SOM Target Markets: USA, EU, UK, Canada, Australia, New Zealand | Pharyngitis AI-Triage + SaMD + Diagnostics Serviceable Available Market ($B) 6 5 4 3 2 1 0 USA EU UK Canada Australia New Zealand Combined SAM (Target Markets): ~$12.7B annually Realistic SOM
Slide 9: Intellectual Property - Patent Portfolio
Intellectual Property - Patent Portfolio Patent 11369318B2 Patent 412983 Patent 3864669 Infection Detection Using Image Data Image processing of streptococcal Image processing of streptococcal Analysis infection in pharyngitis subjects infection in pharyngitis subjects European Union European Union
Slide 10: AI-Powered Diagnostics: Improving Care & Reducing Costs
AI-Powered Diagnostics: Improving Care & Reducing Costs Expanding medical condition diagnostic capability leveraging Light AI QuickScan virtual digital laboratory expands market PI PELINE S TAGE S TATUS Distribution of pediatric Light AI QuickScanTM Group A Strep App Pivotal FDA Trial Stage emergenc
Slide 11: From Pilot to Deployment: Driving Market Adoption
From Pilot to Deployment: Driving Market Adoption STAGE DESCRIPTION Clinical Evidence FDA Pivotal Clinical Trial (U.S.) – Planned Generation New Zealand Pilot Study – Planned Compliance with country-specific healthcare Regulatory Approval regulations Full-scale rollout with training and infrastructu
Slide 12: Regulatory Path
Regulatory Path Health Canada Initial regulatory milestone expected in Q2 2026, paving the way for further international market entries. FDA A pivotal clinical study with major healthcare partners supports FDA pathway for novel device classification. Global Expansion Focus Leveraging Health Canada,
Slide 13: Non-Confidential - Property of Light AI Inc.
Non-Confidential - Property of Light AI Inc. 13 CBOE CA: ALGO FSE: 0HC OTCQB: OHCFF
Slide 14: Experienced Leadership
Experienced Leadership Management John R. Luna Peter Whitehead Mark Orsmond John Tse David Chiu Chief Executive Officer Chief innovation Officer Chief Financial Officer & VP, Commercial Development MS Manager Board Member Corporate Secretary ▪ 30+ years in global MedTech Digital Health ▪ 24 years ex
Slide 15: Advisory Committee
Advisory Committee David Bell David Talan Martin Dawes ▪ Clinical and public health physician with a background in internal ▪ Board-certified in Internal Medicine, Emergency Medicine, and ▪ London University (UK) trained physician scientist and Professor Emeritus of medicine, population health, mode
Slide 16: Summary
Summary 2.5B cases of pharyngitis (sore throat) cases treated Commercialization Initial B2B focus on professional medical community Large Market with expansion to B2C offering annually, approx. 20% bacterial Strep A, 615M SAM. Misdiagnosis drives antibiotic misuse and Antimicrobial Four initial pre-
Slide 17: Thank you
Thank you Contact: investors@light.ai Non-Confidential - Property of Light AI Inc. 17 CBOE CA: ALGO FSE: 0HC OTCQB: OHCFF
Slide 18: Appendix
Appendix Non-Confidential - Property of Light AI Inc. 18 CBOE CA: ALGO FSE: 0HC OTCQB: OHCFF
Slide 19: Global Pharyngitis by Age Group
Global Pharyngitis by Age Group Age Group Share of Global Cases Annual Episodes Children (0–14) ~40–45% 800M – 1.1B Adolescents (15–19) ~10% 200M – 250M Adults (20–64) ~35–40% 700M – 1.0B Seniors (65+) ~5–10% 100M – 200M Sources: WHO Global Burden of Disease; The Lancet Global Health (GAS pharyngiti
Slide 20: Global Pharyngitis TAM – Methodology & Citations
Global Pharyngitis TAM – Methodology & Citations Section 2: TAM Calculations (Global, Annual) AI-Triage TAM 2.25B × 80% applicability × $1.50 = $2.7B TAM Range: $2–5B SaMD TAM Total Global Digital Health 2.25B × 60% applicability × $5.00 = $6.75B TAM TAM (All Modalities): ~$16– Range: $5–12B 30B ann
Slide 21: Why Light AI Can Realistically Capture $100M+ of This TAM
Why Light AI Can Realistically Capture $100M+ of This TAM Serviceable Available Market (SAM) SAM by Geography Geography % Episodes $ SAM North America ~12% $4–6B Europe ~18% $4–6B Asia-Pacific ~40% $5–8B LatAm ~15% $1.5–3B Africa & ME ~15% $1–2B Commercially reachable SAM (OECD + APAC urban): $10–15
Slide 22: Why Light AI Can Realistically Capture $100M+ of This TAM
Why Light AI Can Realistically Capture $100M+ of This TAM Serviceable Available Market (SAM) SAM by Care Setting Care Setting % of Episodes Annual Episodes $ SAM Primary Care / Pediatrics 35% ~790M $6–9B Urgent Care / Retail 20% ~450M $4–6B Clinics Telehealth / Virtual Care 25% ~560M $3–5B Self-Care
Slide 23: Why Light AI Can Realistically Capture $100M+ of This TAM
Why Light AI Can Realistically Capture $100M+ of This TAM Serviceable Obtainable Market (SOM) SOM Scenarios Low Case (0.5% SAM) $12𝐵 × 0.5% = $60𝑀𝐴𝑅𝑅 Base Case (1.0% SAM) $12𝐵 × 1.0% = $120𝑀𝐴𝑅𝑅 Upside Case (2.0% SAM) $12𝐵 × 2.0% = $240𝑀𝐴𝑅𝑅 Credible SOM Range: $60M–$250M ARR…
Slide 24: Global Pharyngitis TAM – Methodology & Citations
Global Pharyngitis TAM – Methodology & Citations Section 1: Volume Anchor (Epidemiology) (Top-left / first block) ~616M annual Group A Streptococcal (GAS) pharyngitis cases globally GAS represents ~20–30% of total pharyngitis (viral + bacterial) Implied global pharyngitis incidence: ~2.0–2.5B episod